Clinical data | |
---|---|
Trade names | Vascor |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a699051 |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | Well absorbed |
Protein binding | 99% |
Metabolism | Hepatic, CYP3A4-mediated |
Elimination half-life | 42 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C24H34N2O |
Molar mass | 366.549 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Bepridil (trade name Vascor) is an diamine calcium channel blocker once used to treat angina pectoris. It is no longer sold in the United States.
It is nonselective. [1]
It has been discussed as a possible option in the treatment of atrial fibrillation. [2]
It has been implicated in causing ventricular arrhythmia ( torsades de pointes).
In June 2015 a research paper [3] was published finding bepridil to result in a 100% survival rate for mice exposed to ebola during an experiment searching for potential pharmaceutical ebola treatments; indicating its potential use in future ebola research and therapy. [4]
A research paper [5] showed that Bepridil inhibited cytopathogenic effects induced by SARS-CoV-2 in Vero E6 cells and in A549 cells in an in vitro assay.
Clinical data | |
---|---|
Trade names | Vascor |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a699051 |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | Well absorbed |
Protein binding | 99% |
Metabolism | Hepatic, CYP3A4-mediated |
Elimination half-life | 42 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C24H34N2O |
Molar mass | 366.549 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Bepridil (trade name Vascor) is an diamine calcium channel blocker once used to treat angina pectoris. It is no longer sold in the United States.
It is nonselective. [1]
It has been discussed as a possible option in the treatment of atrial fibrillation. [2]
It has been implicated in causing ventricular arrhythmia ( torsades de pointes).
In June 2015 a research paper [3] was published finding bepridil to result in a 100% survival rate for mice exposed to ebola during an experiment searching for potential pharmaceutical ebola treatments; indicating its potential use in future ebola research and therapy. [4]
A research paper [5] showed that Bepridil inhibited cytopathogenic effects induced by SARS-CoV-2 in Vero E6 cells and in A549 cells in an in vitro assay.